At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Clinical Trial of Autologous CMV-Specific Cytotoxic T Cells for GBM Patients
In Brief
A Phase 2 clinical trial evaluating Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes, Laboratory Biomarker Analysis, and 2 other interventions for Cytomegalovirus Positive and 5 related conditions. Completed, enrolled 65 participants across 1 site.
Detailed Summary
This phase I/II trial studies the side effects and best dose of autologous cytomegalovirus (CMV)-specific cytotoxic T cells when given together with temozolomide and to see how well they work in treating patients with glioblastoma. Autologous CMV-specific cytotoxic T cells may stimulate the immune system to attack specific tumor cells and stop them from growing or kill them. Drugs used in chemotherapy, such as temozolomide, may work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving autologous CMV-specific cytotoxic T cells with temozolomide may be a better treatment for patients with glioblastoma.
Study Details
Timeline
Interventions
Given IV
Correlative studies
Given PO
Undergo surgery